CXCL12 and neoplasm: Specifically, excluding the only study with prospective design and RT-PCR for evaluating tumor CXCL12 expression [12] showed consistent result (HR: 1.85, 95% CI 1.49–2.29, p < 0.001; I2 = 24%).